<DOC>
	<DOCNO>NCT01307332</DOCNO>
	<brief_summary>There two part investigator sponsor trial ( IST ) : 1 . To perform advanced serial MRI study patient initiate alemtuzumab therapy . 2 . To provide serum sample University Southern California ( USC ) ICAM125 lymphocyte recovery study .</brief_summary>
	<brief_title>Advanced MRI Measures Repair Alemtuzumab Treated Patients</brief_title>
	<detailed_description>Multiple Sclerosis ( MS ) inflammatory demyelinate disease Central Nervous System ( CNS ) . There many form MS ; although majority Relapsing Remitting ( RRMS ) represent approximately 80 % case . The disease appear inflammatory RRMS manifest increase Gadolinium ( Gd ) enhancement MRI increase inflammatory bio-assay marker . Alemtuzumab ; humanize monoclonal antibody target CD52 molecule present T B lymphocytes , natural killer ( NK ) cell , monocyte macrophage ; effect rapid sustain lymphocyte depletion approve treatment B-cell chronic lymphocytic leukemia many country name CAMPATH MabCAMPATH . There two part Investigator Sponsored Trial ( IST ) : 1 . To perform advanced serial MRI study patient initiate alemtuzumab therapy . 2 . To provide serum sample University Southern California ( USC ) ICAM125 lymphocyte recovery study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Signed , informed consent form Age 18 50 year old ( inclusive ) Diagnosis MS per update McDonald criterion , cranial MRI scan demonstrate white matter lesion attributable MS within 10 year screen Onset MS symptom within 15 year screen Neurostatus ( EDSS ) score 0.0 5.0 ( inclusive ) 2 MS attack ( first episode relapse ) occur 24 month prior screen , 1 attack 12 month prior screen , objective neurological sign confirm physician . Received prior therapy MS corticosteroid within 28 day screen ; e.g. , interferon 's , IV immunoglobulin , glatiramer acetate Exposure natalizumab within 6 month screen Any prior exposure mitoxantrone , mycophenolate mofetil , azathioprine , cladribine , cyclophosphamide , cyclosporine A , methotrexate , rituximab , immunosuppressive agent systemic corticosteroid treatment Has progressive form MS History malignancy ( exception basal cell skin carcinoma ) Previous hypersensitivity reaction immunoglobulin product Intolerance pulse corticosteroid , especially history steroid psychosis CD4+ , CD8+ , CD19+ ( i.e. , absolute CD3+CD4+ , CD3+CD8+ , CD19+/mm3 ) count &lt; LLN Screening ; abnormal cell count ( ) return within normal limit , eligibility may reassess Seropositivity human immunodeficiency virus ( HIV ) Significant autoimmune disease ( e.g , immune cytopenia , rheumatoid arthritis , systemic lupus erythematosus , connective tissue disorder ; vasculitis ; inflammatory bowel disease ; severe psoriasis ) Presence antithyroid stimulate hormone ( TSH ) receptor ( TSHR ) antibodies Active infection Latent tuberculosis unless effective antituberculosis therapy complete , active tuberculosis . Infection hepatitis B virus hepatitis C virus Of childbearing potential positive serum pregnancy test Unwilling agree use reliable acceptable contraceptive method throughout study period Major psychiatric disorder adequately control treatment Epileptic seizures adequately control treatment Major systemic disease illness would , opinion Investigator , compromise patient safety interfere interpretation study result Medical , psychiatric , cognitive , condition Confirmed platelet count lower limit normal ( LLN ) evaluate laboratory Screening document 100,000/L within past year sample without clump Prior history invasive fungal infection Cervical high risk human papilloma virus ( HPV ) positivity abnormal cervical cytology abnormal squamous cell undetermined significance ( ASCUS ) . Seropositive Trypanosoma cruzi Human Tlymphotropic virus type I type II ( HTLVI/II ) ( test require endemic region ) Any illness infection ( latent active ) , Investigator 's opinion , could exacerbate alemtuzumab treatment Any hepatic renal function value grade 2 high Screening , exception hyperbilirubinemia due Gilbert 's syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Demyelination</keyword>
	<keyword>Remyelination</keyword>
	<keyword>Tolerogenic</keyword>
	<keyword>T cell</keyword>
	<keyword>Demyelinating Autoimmune Diseases , CNS</keyword>
	<keyword>Autoimmune Diseases Nervous System</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>